Global Human Recombinant Insulin Market Growth, Share, Size, Trends and Forecast (2024 - 2030)

By Brand;

Human Insulin - Humulin, Novolin and Insuman, Insulin Analog - Insulin Lispro[Humalog and Admelog], - Insulin Aspart[Fiasp and Novolog], - Insulin Glulisine[Apidra], - Insulin Detemir[Levemir], - Insulin Degludec[Tresiba], - Insulin Glargine[Lantus, Toujeo, Basaglar and Soliqua] - Insulin Aspart and Insulin Degludec (Ryzodeg), Insulin Degludec and Liraglutide (Xultophy), Insulin Aspart Protamine and Insulin Aspart (Novolog Mix) and Insulin Lispro Protamine, and Insulin Lispro (Humalog Mix).

By Drug Type;

Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, and Long-Acting Insulin.

By Application;

Type 1 Diabetes, Type 2 Diabetes, and Others.

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2020 - 2030).
Report ID: Rn650824923 Published Date: November, 2024 Updated Date: December, 2024

Introduction

Global Human Recombinant Insulin Market (USD Million), 2020 - 2030

In the year 2023, the Global Human Recombinant Insulin Market was valued at USD 4,576.34 million. The size of this market is expected to increase to USD 7,445.29 million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of 7.2%.

The global human recombinant insulin market stands at the forefront of modern medicine, representing a pivotal advancement in diabetes management. Recombinant insulin, derived from genetic engineering techniques, has revolutionized the treatment landscape for millions worldwide, offering safer and more effective alternatives to traditional insulin sources. Its advent has significantly reduced the reliance on animal-derived insulin, mitigating concerns over allergic reactions and supply limitations.

One of the primary drivers propelling the growth of the human recombinant insulin market is the escalating prevalence of diabetes mellitus across the globe. With diabetes emerging as a pressing public health concern, particularly in developing nations witnessing rapid urbanization and lifestyle changes, the demand for advanced insulin therapies continues to surge. Moreover, the aging population, coupled with sedentary lifestyles and unhealthy dietary habits, further exacerbates the diabetes epidemic, necessitating the adoption of innovative treatment modalities.

Technological advancements in genetic engineering and biotechnology have ushered in a new era of insulin production, characterized by enhanced purity, potency, and safety profiles. Manufacturers are investing heavily in research and development endeavors to refine recombinant insulin formulations, striving for improved efficacy and patient compliance. Furthermore, the proliferation of biosimilar insulin products has fostered market competition, driving down costs and expanding access to essential diabetes medications. Concerted efforts by healthcare organizations and regulatory authorities to promote diabetes awareness, early diagnosis, and optimal disease management have augmented the uptake of recombinant insulin therapies. Collaborative initiatives aimed at improving healthcare infrastructure, ensuring affordable access to insulin, and fostering patient education are instrumental in addressing the multifaceted challenges posed by diabetes. As the global human recombinant insulin market continues to evolve, fueled by technological innovation and strategic collaborations, it holds immense promise in alleviating the burden of diabetes and enhancing patient outcomes worldwide.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Brand
    2. Market Snapshot, By Drug Type
    3. Market Snapshot, By Application
    4. Market Snapshot, By Distribution Channel
    5. Market Snapshot, By Region
  4. Global Human Recombinant Insulin Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising diabetic population
        2. Technological advancements in insulin production
        3. Increasing healthcare expenditure
        4. Growing awareness about diabetes
        5. Favorable government initiatives
      2. Restraints
        1. High cost of insulin
        2. Stringent regulatory requirements
        3. Limited accessibility in rural areas
        4. Adverse effects associated with insulin
        5. Competition from alternative treatments
      3. Opportunities
        1. Emerging markets' untapped potential
        2. Development of novel insulin formulations
        3. Collaborations for research and development
        4. Personalized insulin therapies
        5. Increasing focus on preventive healthcare
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Human Recombinant Insulin Market, By Brand, 2020 - 2030 (USD Million)
      1. Human Insulin
        1. Humulin
        2. Novolin
        3. Insuman
      2. Insulin Analog
        1. Insulin Lispro
          1. Segment Trends
          2. Humalog
          3. Admelog
        2. Insulin Aspart
          1. Fiasp
          2. Novolog
        3. Insulin Glulisine
          1. Apidra
        4. Insulin Detemir
          1. Levemir
        5. Insulin Degludec
          1. Tresiba
        6. Insulin Glargine
          1. Lantus
          2. Toujeo
          3. Basaglar
          4. Soliqua
        7. Insulin in Fixed-dose Combination
          1. Insulin Aspart and Insulin Degludec (Ryzodeg)
          2. Insulin Degludec and Liraglutide (Xultophy)
          3. Insulin Aspart Protamine and Insulin Aspart (Novolog Mix)
          4. Insulin Lispro Protamine and Insulin Lispro (Humalog Mix)
    2. Global Human Recombinant Insulin Market, By Drug Type, 2020 - 2030 (USD Million)
      1. Rapid-Acting Insulin
      2. Short-Acting Insulin
      3. Intermediate-Acting Insulin
      4. Long-Acting Insulin
    3. Global Human Recombinant Insulin Market, By Application, 2020 - 2030 (USD Million)
      1. Type 1 Diabetes
      2. Type 2 Diabetes
      3. Others
    4. Global Human Recombinant Insulin Market, By Distribution Channel, 2020 - 2030 (USD Million)
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    5. Global Human Recombinant Insulin Market, By Geography, 2020 - 2030 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America

  6. Competitive Landscape
    1. Company Profiles
      1. Eli Lilly and Company
      2. Novo Nordisk A/S
      3. Sanofi S.A
      4. Biocon Limited
      5. Wockhardt Ltd
      6. Mylan N.V
      7. Sedico Pharmaceutical Co
      8. Exir Pharmaceutical Company
  7. Analyst Views
  8. Future Outlook of the Market